| abstract |
Therapeutic compounds of formula (I) wherein X is CH 2 or SO 2 ; R 1 is an optionally substituted aryl or heteroaryl ring; R 2 and R 3 are various specified groups, R 4 is a group NHCOR 15 , NHSO 2 R 15 or OCONR 16 R 17 where R 15 , R 16 and R 17 are various defined groups; and R 5 , R 6 and R 7 are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups; and further provided that when R 4 is a group NHCOR 15 , R 15 is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by MCP-1 (monocyte chemoattractant protein-1) or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease. |